A detailed history of Citizens Financial Group Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Citizens Financial Group Inc holds 99,228 shares of ABBV stock, worth $16.9 Million. This represents 0.4% of its overall portfolio holdings.

Number of Shares
99,228
Previous 95,154 4.28%
Holding current value
$16.9 Million
Previous $16.3 Million 20.07%
% of portfolio
0.4%
Previous 0.37%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$163.84 - $199.33 $667,484 - $812,070
4,074 Added 4.28%
99,228 $19.6 Million
Q2 2024

Aug 09, 2024

BUY
$154.79 - $180.76 $10.9 Million - $12.7 Million
70,484 Added 285.71%
95,154 $16.3 Million
Q1 2024

May 17, 2024

SELL
$159.82 - $182.1 $579,986 - $660,840
-3,629 Reduced 12.82%
24,670 $4.49 Million
Q4 2023

Feb 02, 2024

BUY
$137.6 - $154.97 $1.2 Million - $1.35 Million
8,689 Added 44.31%
28,299 $4.39 Million
Q3 2023

Nov 13, 2023

SELL
$133.59 - $154.65 $263,172 - $304,660
-1,970 Reduced 9.13%
19,610 $2.92 Million
Q2 2023

Aug 04, 2023

SELL
$132.51 - $164.9 $44,655 - $55,571
-337 Reduced 1.54%
21,580 $2.91 Million
Q1 2023

May 10, 2023

BUY
$144.61 - $166.54 $733,317 - $844,524
5,071 Added 30.1%
21,917 $3.49 Million
Q4 2022

Feb 09, 2023

BUY
$138.31 - $165.87 $62,239 - $74,641
450 Added 2.74%
16,846 $2.72 Million
Q3 2022

Nov 10, 2022

SELL
$134.21 - $153.93 $195,007 - $223,660
-1,453 Reduced 8.14%
16,396 $2.2 Million
Q2 2022

Aug 05, 2022

SELL
$137.62 - $174.96 $128,812 - $163,762
-936 Reduced 4.98%
17,849 $2.73 Million
Q1 2022

May 12, 2022

BUY
$131.98 - $163.75 $171,442 - $212,711
1,299 Added 7.43%
18,785 $3.05 Million
Q4 2021

Feb 10, 2022

SELL
$107.43 - $135.93 $359,568 - $454,957
-3,347 Reduced 16.07%
17,486 $2.37 Million
Q3 2021

Nov 05, 2021

SELL
$106.4 - $120.78 $1.29 Million - $1.46 Million
-12,101 Reduced 36.74%
20,833 $2.25 Million
Q2 2021

Aug 04, 2021

BUY
$105.21 - $117.21 $1.68 Million - $1.87 Million
15,944 Added 93.84%
32,934 $3.71 Million
Q1 2021

May 14, 2021

BUY
$102.3 - $112.62 $135,445 - $149,108
1,324 Added 8.45%
16,990 $1.84 Million
Q4 2020

Feb 11, 2021

SELL
$80.49 - $108.67 $165,084 - $222,882
-2,051 Reduced 11.58%
15,666 $1.68 Million
Q3 2020

Nov 12, 2020

SELL
$85.91 - $100.83 $1.29 Million - $1.51 Million
-14,984 Reduced 45.82%
17,717 $1.55 Million
Q2 2020

Aug 12, 2020

BUY
$73.37 - $98.18 $17,535 - $23,465
239 Added 0.74%
32,701 $3.21 Million
Q1 2020

May 08, 2020

BUY
$64.5 - $97.79 $932,928 - $1.41 Million
14,464 Added 80.36%
32,462 $2.47 Million
Q4 2019

Feb 07, 2020

BUY
$72.13 - $90.25 $206,724 - $258,656
2,866 Added 18.94%
17,998 $1.59 Million
Q3 2019

Nov 01, 2019

SELL
$62.98 - $75.72 $302,807 - $364,061
-4,808 Reduced 24.11%
15,132 $1.15 Million
Q2 2019

Aug 09, 2019

SELL
$65.7 - $83.98 $193,026 - $246,733
-2,938 Reduced 12.84%
19,940 $1.45 Million
Q1 2019

May 09, 2019

SELL
$77.14 - $90.79 $22,370 - $26,329
-290 Reduced 1.25%
22,878 $1.84 Million
Q4 2018

Feb 11, 2019

SELL
$77.85 - $96.01 $6,461 - $7,968
-83 Reduced 0.36%
23,168 $2.14 Million
Q3 2018

Nov 02, 2018

SELL
$88.91 - $98.84 $79,218 - $88,066
-891 Reduced 3.69%
23,251 $2.2 Million
Q2 2018

Jul 27, 2018

SELL
$89.78 - $106.23 $203,172 - $240,398
-2,263 Reduced 8.57%
24,142 $2.24 Million
Q1 2018

May 11, 2018

SELL
$92.01 - $123.21 $263,056 - $352,257
-2,859 Reduced 9.77%
26,405 $2.5 Million
Q4 2017

Feb 09, 2018

SELL
$89.56 - $98.21 $125,563 - $137,690
-1,402 Reduced 4.57%
29,264 $2.83 Million
Q3 2017

Nov 13, 2017

SELL
$69.85 - $89.22 $652,818 - $833,850
-9,346 Reduced 23.36%
30,666 $2.73 Million
Q2 2017

Aug 10, 2017

BUY
N/A
40,012
40,012 $2.9 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $302B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Citizens Financial Group Inc Portfolio

Follow Citizens Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citizens Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citizens Financial Group Inc with notifications on news.